|
|
|
List of publications
42 Lara Pes,
Stephan David Koester, Johannes Pall Magnusson, Serghei Chercheja, Federico
Medda, Khalid Abu Ajaj, Didier Rognan, Steffen Daum, Friederike Inga
Nollmann, Javier Garcia Fernandez, Patricia Perez Galan, Heidi-Kristin
Walter, Anna Warnecke, Felix Kratz: Novel auristatin E-based
albumin-binding prodrugs with compelling anticancer efficacy in vivo, Journal
of Controlled Release, 2019, 296, 81–92
41 Johannes Pall Magnusson, Steffen
Daum, Javier Garcia Fernandez, Serghei Chercheja, Federico Medda,
Friederike Inga Nollmann, Lara Pes, Stephan David Koester, Patricia Perez
Galan, Anna Warnecke, Khalid Abu Ajaj, Felix Kratz: Development of
an imaging agent for determining albumin uptake in solid tumors, Nuclear
Medicine and Molecular Imaging, 2019, 53,
189–198
40 Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike Inga Nollmann,
Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Johannes Pall
Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen
Daum: Imaging agents for radiolabeling exogenous and endogenous albumin, US
Provisional application, Filed: July 24, 2018
39 Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike Inga Nollmann,
Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin. Walter,
Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico
Medda, Steffen Daum: Albumin-binding prodrugs of auristatin E derivatives, PCT
application, Filed: November 30, 2018
38 Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike Inga Nollmann,
Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin.
Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan,
Federico Medda, Steffen Daum: Maytansinoid-Based Drug Delivery Systems, PCT
application, Filed: November 30, 2018
37 Stephan David Koester, Lara Pes,
Johannes Pall. Magnusson, Serghei Chercheja, Federico Medda, Friederike I.
Nollmann, Patricia Perez Galan, Javier Garcia Fernandez, Steffen Daum,
Heidi-Kristin Walter, Khalid Abu
Ajaj, Anna Warnecke, Felix Kratz: Superior efficacy of novel
albumin-binding auristatin E-based prodrugs compared to auristatin E in a
panel of human xenograft models in mice.
Proc. Amer. Assoc. Cancer
Res. 2018, 78 (13 Suppl),
3703.
36 Friederike I. Nollmann, Patricia
Perez Galan, Javier Garcia Fernandez, Heidi-Kristin Walter, Johannes Pall.
Magnusson, Federico Medda, Felix Kratz, Stephan David Koester, Khalid Abu Ajaj, Lara Pes, Serghei
Chercheja, Anna Warnecke: Structure-activity relationship studies and biological
evaluation of novel maytansinoids, a class of highly selective tubulin
inhibitors.
Proc. Amer. Assoc. Cancer Res.
2018, 78 (13 Suppl),1657.
35 Friederike I. Nollmann, Patricia
Perez Galan, Javier Garcia Fernandez, Heidi-Kristin, Johannes Pall. Magnusson,
Federico Medda, Felix Kratz, Stephan David Koester, Khalid Abu Ajaj, Lara Pes, Serghei Chercheja, Anna Warnecke:
Novel albumin-binding maytansinoids inducing long-term partial and complete
tumor regressions in several human cancer xenograft models in nude mice. Proc.
Amer. Assoc. Cancer Res. 2018, 78 (13 Suppl), 2661
34 Khalid
Abu Ajaj, A decade of targeted therapy for non-small cell lung cancer, J
Pulmonol Respir Res. 2017, 1, 23-28.
33 Khalid Abu Ajaj, Stephan
David Koester, Friederike Inga Nollmann, Simon Waltzer, Olga Fuchs, André
Warnecke, Felix Kratz: LADR™: A novel linker activated drug release
technology for drug delivery, Proc. Amer. Assoc. Cancer Res. 2016, 76, 4858
32 Felix Kratz, Khalid
Abu Ajaj, Andre Warnecke, Stephan
David Koester, Friederike Inga Nollmann, Simon Waltzer, Olga Fuchs, Fernandez Javier
Garcia: Delivery systems for controlled drug release,
2016, WO 2016/6205738 A3
31 Leslie Walker, Eddie Perkins, Khalid
Abu Ajaj, Felix Kratz, Drazen Raucher: Utilizing the
targeting properties of elastin-like polypeptide to safely deliver a potent
doxorubicin. Proc. Amer.
Assoc. Cancer Res. 2013, 54, 4507
30 Katrin Hochdoerffer, Khalid Abu
Ajaj, Cynthia Schäfer-Obodozie, Felix Kratz: Development of novel
bisphosphonate prodrugs of doxorubicin for targeting bone metastases that
are cleaved pH dependently or by cathepsin B: Synthesis, cleavage
properties, and binding properties to hydroxyapatite as well as bone
matrix. Journal of Medicinal Chemistry, 2012, 55 (17),
7502–7515
29 Khalid Abu Ajaj, Ralph
Graeser, Felix Kratz: Zosuquidar and an albumin-binding prodrug of
zosuquidar reverse multidrug resistance in breast cancer cells of
doxorubicin and an albumin-binding prodrug of doxorubicin. Breast Cancer
Research and Treatment, 2012, 134 (1),
117–129
28 Khalid Abu Ajaj, Naser
El-Abadla, Pia Welker, Samar Azab, Reiner Zeisig, Iduna Fichtner, Felix
Kratz: Comparative evaluation of the biological properties of reducible and
acid-sensitive folate prodrugs of a highly potent doxorubicin derivative. European Journal
of Cancer, 2012, 48 (13),
2054–2065
27 Khalid Abu
Ajaj, Irina Nickeleit, Ronald Frank: Development of
calmodulin inhibitors from
screening of chemical microarray libraries. 3rd European
Chemical Biology Symposium ECBS2012, P7, 67,
Vienna, Austria, July 1–3, 2012
26 Khalid Abu Ajaj, Ralph
Graeser, Yeonyu Lee, Felix Kratz: Prodrug-mediated reversal of
multidrug resistance in breast cancer cells. Proc. Amer. Assoc. Cancer Res. 2012,
53, 3575
25 Khalid Abu Ajaj, Felix Kratz:
Clinical Experience with Drug-Polymer Conjugates. In: Drug Delivery in Oncology - From Basic
Research to Cancer Therapy. Edited by Felix
Kratz, Henning Steinhagen, Peter Senter, 1 ed;
Wiley-VCH: Weinheim, 2011: 839–884
24 Bakheet Elsadek, Ralph Graeser,
Norbert Esser, Cynthia Schäfer-Obodozie, Chizuko Tsurumi, Khalid
Abu Ajaj, André Warnecke, Clemens Unger, Tahia Saleem, Felix Kratz: A
novel albumin-binding prodrug of doxorubicin with improved efficacy against
prostate cancer metastases. Prostate Cancer
and Prostatic Diseases, 2011, 14 (1), 14–21
23 Teuta Opacak-Bernardi, Leslie Robinson,
Khalid Abu Ajaj, Felix Kratz, Drazen Raucher: In vitro
Evaluation of a Thermally Targeted Conjugate of a Highly Potent Doxorubicin
Derivative. Proc. Amer. Assoc.
Cancer Res. 2011, 52, 3226
22 Khalid Abu Ajaj, Naser El-Abadla,
Pia Welker, Samar Azab, Reiner Zeisig, Iduna Fichtner, Felix
Kratz: Biological evaluation of float prodrugs with a highly toxic
derivative of doxorubicin. Proc. Amer.
Assoc. Cancer Res. 2011, 52, 4436
21 Bakheet Elsadek, Ralph Graeser,
Norbert Esser, Cynthia Schäfer-Obodozie, Khalid Abu Ajaj,
Clemens Unger, André Warnecke, Tahia Saleem, Nagla El-Melegy, Hafez Madkor,
Felix Kratz: Development of a novel prodrug of paclitaxel that is cleaved
by prostate-specific antigen: an in vitro and in vivo evaluation study. European Journal
of Cancer, 2010, 46 (18), 3434–3444
20 Khalid Abu Ajaj, Cynthia
Schaefer-Obodozie, Norbert Esser, Felix Kratz: Development of
macromolecular prodrugs with proteasome inhibitors. 8th International Symposium on Polymer Therapeutics, Valencia,
Spain, 2010, Abstract
book, P59, 98
19 Bakheet Elsadek, Ralph Graeser,
Norbert Esser, Khalid Abu Ajaj, Tahia Saleem, Nagla El
Melegy, Hafez Madkor, Felix Kratz: Development of a novel water-soluble
prodrug of paclitaxel that is cleaved by prostate-specific antigen (PSA):
In vitro and in vivo evaluation. Proc. Amer. Assoc. Cancer Res.2010, 51, LB-39
18 Khalid Abu Ajaj, Martin
Biniossek, Felix Kratz: Development of protein-binding bifunctional linkers
for a new generation of dual-acting prodrugs. Bioconjugate Chemistry, 2009,
20 (2), 390–396
17 Khalid Abu Ajaj, Felix Kratz:
Development of dual-acting prodrugs for circumventing multidrug resistance.
Bioorganic & Medicinal Chemistry Letters, 2009,
19 (3), 955–1000
16 Khalid Abu Ajaj, Ralph
Graeser, Iduna Fichtner, Felix Kratz: In vitro and in vivo
study of an albumin-binding prodrug of doxorubicin that is cleaved by
cathepsin B. Cancer Chemotherapy & Pharmacology, 2009,
64 (2), 413–418
15 Khalid Abu Ajaj, Ralph
Graeser, Felix Kratz: Development of a dual-acting prodrug with
doxorubicin and the P-glycoprotein inhibitor ONT-093 for circumventing
multidrug resistance. Proc. Amer. Assoc. Cancer Res. 2009, 50, 637
14 Khalid Abu Ajaj, Felix Kratz: Development
of prodrugs for
combination chemotherapy. Proc.
Amer. Assoc. Cancer Res. 2009, 50, 661
13 Khalid Abu Ajaj, Ralph
Graeser, Iduna Fichtner, Felix Kratz: In vitro and in vivo
study of an albumin-binding prodrug of doxorubicin that is cleaved by
cathepsin B. Proc. Amer. Assoc.
Cancer Res. 2009, 50, 3686
12 Gisa Gerold, Khalid Abu Ajaj,
Michael Bienert, Hans-Jürgen Laws, Arturo Zychlinsky, Juana de
Diego: A Toll-like receptor 2-integrin β3 complex senses bacterial
lipopeptides via vitronectin. Nature Immunology, 2008, 9 (7),
761–768
11 Felix Kratz, Claudia Ryppa, Khalid
Abu Ajaj: Development of ligand-based and dual acting prodrugs as the
next generation of albumin-binding prodrugs. 7th International Symposium on Polymer Therapeutics, Valencia,
Spain, 2008, Abstract book, 72
10 Khalid Abu Ajaj, Ralph Graeser,
Christoph Schaechtele, Felix Kratz: Development
of prodrugs for combination chemotherapy. Proc. Amer. Assoc. Cancer Res. 2008, 49, 1288
9 Gisa Gerold,
Hans-Jürgen Laws, Khalid Abu Ajaj, Michael Bienert, Arturo Zychlinsky, Juana de Diego: Toll-like
receptor 2 dependent pattern recognition requires vitronectin and beta3
integrin. Keystone Symposium,
Keystone, Colorado, USA, 2008, Abstract
book
8 Felix Kratz , Khalid Abu Ajaj, André Warnecke:
Anticancer carrier-linked prodrugs in clinical trials. Expert Opinion on
Investigational Drugs, 2007, 16 (7), 1037–1058
7 Khalid Abu Ajaj, Felix
Kratz: Development of new albumin-binding dual acting prodrugs to overcome
P-glycoprotein-mediated multidrug
resistance. Proc. Amer. Assoc.
Cancer Res.
2007, 48, 2267
6 Ines Sauer, Heike Nikolenko,
Sandro Keller, Khalid Abu Ajaj, Michael Bienert, Margitta Dathe:
Dipalmitoylation of a cellular uptake-mediating apolipoprotein E-derived
peptide as a promising modification for stable anchorage in liposomal drug
carriers. Biochimica et Biophysica Acta (BBA) - Biomembranes,
2006, 1758 (4), 552–561
5 Gisa Gerold, Juana de
Diego, Khalid Abu Ajaj, Michael Bienert, Arturo Zychlinsky: An acute
phase serum protein negatively regulates the interaction of bacterial
lipoprotein with toll-like receptor 2. Keystone Symposium, Steamboat Springs, Colorado, USA, 2005, Abstract book
4 Juana de Diego, Khalid Abu Ajaj,
Gisa Gerold, Micael Bienert, Arturo Zychlinsky: An acute phase serum
protein negatively regulates the interaction of bacterial lipoprotein with
Toll-like receptor 2. EURESCO conferences, San Feliu de Guixols,
Spain, 2004, Abstract book
3 Khalid Abu Ajaj, Lothar
Hennig, Matthias Findeisen, Sabine Giesa, Dietrich Müller, Peter Welzel:
Synthesis of a complex disaccharide precursor of phosphonate analogues of
the antibiotic moenomycin A12. Tetrahedron, 2002,
58 (42), 8439–8451
2 Khalid Abu Ajaj, Yang
Guangbin, Svetlana Zakharova, Peter Welzel: Synthesis of phosphonate
analogues of moenomycin A12. Biology of Bacterial Natural
Substance Producers Workshop, Berlin, Germany, 2001, Abstract book
1 Marwan Kamal, Samir Al-Taweel,
Mustafa El-Abadelah, Khalid Abu Ajaj: Synthesis of α-thiophene
oligomers via organotin compounds. Phosphorus,
Sulfur, and Silicon and the Related Elements, 1997,
126 (1), 65–74
|
|
|